• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of September 20

Video

Here are the top 5 biosimilar articles for the week of September 20, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 20, 2021.

Number 5: Investigators in China reported positive equivalence findings from a phase 3 trial of a bevacizumab biosimilar candidate (MIL60) and platinum-based chemotherapy as first-line treatment in Chinese patients with recurrent or advanced non–small cell lung cancer (NSCLC).

Number 4: A phase 3 study of a trastuzumab biosimilar candidate and the reference product (Herceptin) has demonstrated equivalence in patients with human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer, according to findings presented at the European Society for Medical Oncology (ESMO) Congress 2021.

Number 3: Alvotech gained an EU marketing recommendation for AVT02, a proposed adalimumab biosimilar; New Zealand may give preferential status to Amgen's adalimumab biosimilar; and BioFactura looks to deliver ustekinumab via a robotic pill.

Number 2: Alvotech said the FDA review of its high concentration, citrate-free adalimumab biosimilar candidate (AVT02) is held up by pandemic-related curbs on overseas inspections.

Number 1: The FDA has approved the first ranibizumab biosimilar (Byooviz, SB11) for multiple ophthalmologic conditions, although market launch is at least 9 months away, owing to patent protections on the originator product.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Here are the top 5 biosimilar articles for the week of June 9, 2025.
Here are the top 5 biosimilar articles for the week of June 2, 2025.
Here are the top 5 biosimilar articles for the week of May 26, 2025.
Elena Wolff-Holz, MD.
Here are the top 5 biosimilar articles for the week of May 19, 2025.
Here are the top 5 biosimilar articles for the week of May 12, 2025.
Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics
Here are the top 5 biosimilar articles for the week of May 5, 2025.
Here are the top 5 biosimilar articles for the week of April 28, 2025.
Related Content
© 2025 MJH Life Sciences

All rights reserved.